{"id":"W2903241832","doi":"10.1016/j.eururo.2018.11.033","title":"Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint","year":2018,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Mitoxantrone; Cabozantinib; Prostate cancer; Clinical endpoint; Prednisone; Enzalutamide; Oncology; Randomized controlled trial; Internal medicine; Cancer; Anesthesia; Surgery; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001703243,0.001467007,0.00224354,0.0005103929,0.0005058605,0.0009860491,0.0007068618,0.001565286,0.007459905],"category_scores_gemma":[0.001896266,0.0005659754,0.002218774,0.0004865572,0.0008440506,0.0007328804,0.0003154841,0.002337716,0.0008297944],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008036037,"about_ca_system_score_gemma":0.001676384,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001374547,"about_ca_topic_score_gemma":0.004569246,"domain_scores_codex":[0.9993858,0.0003451659,0.00003636149,0.00008143364,0.0000698248,0.00008138519],"domain_scores_gemma":[0.9990849,0.0002252602,0.0002892955,0.00005242936,0.00006679246,0.0002811974],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9752545,0.005420096,0.0004248891,0.001035264,0.000854871,0.0000393229,0.00004744161,0.0003053889,0.002234619,0.00009030387,0.0008521609,0.01344109],"study_design_scores_gemma":[0.9653443,0.03255667,0.0009894129,0.00003589759,0.0002598765,0.00002626492,0.00001027701,0.0002264578,0.000155075,0.00007817474,0.0003101741,0.000007512827],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9708237,0.01199625,0.0008035847,0.001338286,0.000823395,0.009564212,0.001721451,0.0002539613,0.002675181],"genre_scores_gemma":[0.9771656,0.004643504,0.001886745,0.001671022,0.0006015145,0.01025656,0.001153344,0.00003405424,0.002587596],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007459905,"threshold_uncertainty_score":0.02495587,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0304704911735106,"score_gpt":0.3315535634413619,"score_spread":0.3010830722678513,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}